Last reviewed · How we verify

NCT07222228

A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception

Not yet recruiting Phase 2 Last updated 29 October 2025
What this trial tests

Phase 2 trial testing Levonorgestrel butanoate in Healthy Women in 165 participants. Not yet recruiting.

Timeline
1 April 2026
Primary endpoint
31 December 2028
31 March 2029

Quick facts

Lead sponsorPremier Research
PhasePhase 2
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment165
Start date1 April 2026
Primary completion31 December 2028
Estimated completion31 March 2029

Drugs / interventions tested

Conditions studied

Sponsor

Premier Research — full company profile →

Who can join

Adults 18 to 35, female only, with Healthy Women or Female Contraception. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, open-label, Phase 2b study to evaluate the efficacy and safety of 2 LB SQ injections administered at a 4-month (approximately 17 weeks) interval for female contraception.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Healthy Women

Currently open trials in the same condition.

Other Premier Research trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07222228.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing